SCI时时刷

search
The Impact of Prior Single-Gene Testing on Comprehensive Genomic Profiling Results for Patients with Non-Small Cell Lung Cancer
The Impact of Prior Single-Gene Testing on Comprehensive Genomic Profiling Results for Patients with Non-Small Cell Lung Cancer
Tissue-based broad molecular profiling of guideline-recommended biomarkers is advised for the therapeutic management of pa...
Epidemiology and Real-World Treatment of Incident Diffuse Large B-cell Lymphoma (DLBCL): A German Claims Data Analysis
Epidemiology and Real-World Treatment of Incident Diffuse Large B-cell Lymphoma (DLBCL): A German Claims Data Analysis
The objective of this study was to investigate the prevalence, incidence, and treatment patterns (treatment regimens, swit...
Small Molecule Menin Inhibitors: Novel Therapeutic Agents Targeting Acute Myeloid Leukemia with KMT2A Rearrangement or NPM1 Mutation
Small Molecule Menin Inhibitors: Novel Therapeutic Agents Targeting Acute Myeloid Leukemia with KMT2A Rearrangement or NPM1 Mutation
Recent advances have included insights into the clinical value of genomic abnormalities in acute myeloid leukemia (AML) an...
Acute Thrombocytopenia Complicating the Initial Administration of Obinutuzumab: Is It More Frequent Than We Think?
Acute Thrombocytopenia Complicating the Initial Administration of Obinutuzumab: Is It More Frequent Than We Think?
Thrombocytopenia has been reported more frequently with obinutuzumab in clinical trials where it was directly compared wit...
Non-Small Cell Lung Cancer Testing on Reference Specimens: An Italian Multicenter Experience
Non-Small Cell Lung Cancer Testing on Reference Specimens: An Italian Multicenter Experience
Biomarker testing is mandatory for the clinical management of patients with advanced non-small cell lung cancer (NSCLC). M...
Patient Versus Physician Perspective in the Management of Chronic Myeloid Leukemia During Treatment with Tyrosine Kinase Inhibitors
Patient Versus Physician Perspective in the Management of Chronic Myeloid Leukemia During Treatment with Tyrosine Kinase Inhibitors
Chronic myeloid leukemia (CML) is a chronic disease with treatment-free remission (TFR) increasingly regarded as a feasibl...
Diversity in Oncology Clinical Trials: Current Landscape for Industry-Sponsored Clinical Trials in Asia
Diversity in Oncology Clinical Trials: Current Landscape for Industry-Sponsored Clinical Trials in Asia
There has been a growing recognition on the importance of diversity in clinical trials. Existing research has highlighted ...
Adjuvant CDK4/6 Inhibitors for Early Breast Cancer: How to Choose Wisely?
Adjuvant CDK4/6 Inhibitors for Early Breast Cancer: How to Choose Wisely?
Assuming that ribociclib will be approved in the adjuvant setting on the basis of the recent findings from NATALEE, some p...
From Incidence to Intervention: A Comprehensive Look at Breast Cancer in South Africa
From Incidence to Intervention: A Comprehensive Look at Breast Cancer in South Africa
The formidable impact of breast cancer extends globally, with South Africa facing pronounced challenges, including signifi...
Is HER2-Low a New Clinical Entity or Merely a Biomarker for an Antibody Drug Conjugate?
Is HER2-Low a New Clinical Entity or Merely a Biomarker for an Antibody Drug Conjugate?
Wolff AC, et al. HER2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists Cli...
Early Systemic Anti-neoplastic Treatment Post SARS-CoV-2 Infection in Patients with Breast Cancer
Early Systemic Anti-neoplastic Treatment Post SARS-CoV-2 Infection in Patients with Breast Cancer
It is unclear how soon after severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection it is safe to resume s...
A Meta-analysis of Surgical Outcomes of T4a and Infranotch T4b Oral Cancers
A Meta-analysis of Surgical Outcomes of T4a and Infranotch T4b Oral Cancers
To determine the overall surgical outcomes of infranotch T4b oral cancers and compare them with T4a oral cancers. PubMed, ...
Shared Decision-Making on Using a CDK4/6 Inhibitor plus an Aromatase Inhibitor for HR+/HER2− Metastatic Breast Cancer: A Podcast
Shared Decision-Making on Using a CDK4/6 Inhibitor plus an Aromatase Inhibitor for HR+/HER2− Metastatic Breast Cancer: A Podcast
Shared decision-making involves patients engaging with their physicians to make informed decisions regarding treatment sel...
The Landscape of BRCA Mutations among Egyptian Women with Breast Cancer
The Landscape of BRCA Mutations among Egyptian Women with Breast Cancer
Deleterious germline mutations in BRCA1 and BRCA2 genes are associated with a high risk of breast and ovarian cancer. In m...
Recent Advances in Gynecological Malignancies: Focus on ASCO 2023
Recent Advances in Gynecological Malignancies: Focus on ASCO 2023
Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global cancer statistics 2020: GLOBOCAN estim...
Genetic Testing in Metastatic Breast Cancer in the USA: A Podcast
Genetic Testing in Metastatic Breast Cancer in the USA: A Podcast
This podcast highlights the importance of genetic testing in patients with metastatic breast cancer, with a specific focus...